Sera Prognostics (NASDAQ:SERA) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Sera Prognostics (NASDAQ:SERAGet Rating) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports.

According to Zacks, “Sera Prognostics Inc. is a women’s health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY. “

A number of other equities research analysts have also recently issued reports on the stock. Citigroup cut shares of Sera Prognostics from a buy rating to a neutral rating in a research report on Wednesday, March 30th. Berenberg Bank assumed coverage on shares of Sera Prognostics in a research report on Wednesday, April 27th. They set a buy rating for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Buy and an average target price of $18.50.

Shares of Sera Prognostics stock opened at $1.70 on Wednesday. Sera Prognostics has a fifty-two week low of $1.69 and a fifty-two week high of $15.50. The firm has a fifty day moving average price of $2.90 and a two-hundred day moving average price of $6.33.

Sera Prognostics (NASDAQ:SERAGet Rating) last announced its quarterly earnings data on Tuesday, March 29th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.12). Sera Prognostics had a negative net margin of 38,185.05% and a negative return on equity of 80.22%. On average, equities research analysts expect that Sera Prognostics will post -1.46 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of SERA. Bank of America Corp DE grew its holdings in Sera Prognostics by 768.8% during the 4th quarter. Bank of America Corp DE now owns 3,597 shares of the company’s stock worth $25,000 after acquiring an additional 3,183 shares during the last quarter. American International Group Inc. bought a new stake in Sera Prognostics during the 3rd quarter worth about $29,000. Deutsche Bank AG bought a new stake in Sera Prognostics during the 3rd quarter worth about $30,000. Frontier Wealth Management LLC bought a new stake in Sera Prognostics during the 1st quarter worth about $30,000. Finally, Aspiriant LLC bought a new stake in Sera Prognostics during the 1st quarter worth about $62,000. 63.20% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile (Get Rating)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.

Further Reading

Get a free copy of the Zacks research report on Sera Prognostics (SERA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.